AGP
SLNO

Artia Global Partners’s Soleno Therapeutics SLNO Stock Holding History

Artia Global Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$2.31M – 59
2025
Q4 		$2.31M Buy
+50,000
New +$2.74M 0.33% 37
2025
Q2 		– Sell
-100,000
Closed -$7.14M – 45
2025
Q1 		$7.14M Buy
+100,000
New +$4.87M 1.81% 15

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Artia Global Partners's SLNO Position: Q1 2026 in Review

Artia Global Partners reduced its Soleno Therapeutics (SLNO) stake by 87% in Q1 2026, selling an estimated $18.2M and leaving 68,490 shares worth $2.29M. The position accounts for 0.46% of the portfolio, ranked #35.

Artia Global Partners first reported a position in SLNO in Q1 2024 and has held it in 9 quarters since. The position peaked at $45.4M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Artia Global Partners held 68,490 shares of Soleno Therapeutics worth $2.29M as of Q1 2026.
  • Artia Global Partners sold 465,208 Soleno Therapeutics shares in Q1 2026, an estimated $18.2M.
  • Soleno Therapeutics made up 0.46% of Artia Global Partners's portfolio in Q1 2026, its #35 holding.
  • Artia Global Partners first reported a position in Soleno Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Artia Global Partners's Soleno Therapeutics position peaked at $45.4M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.